Abstract
Introduction. One of the characteristics of COVID-19, caused by the SARS-CoV-2 virus, is the broad, nonspecific nature of the pathological processes that develop in almost all organs and organ systems of the human body. At the same time, the development of endothelial dysfunction has been identified by many investigators as the pathological process that integrates these disorders and is considered the primary pathophysiological mechanism in severe cases.
Aim. Post-COVID-19 infection survivors in 2021–2022 (n = 502) underwent a Flow-Mediated Dilation (FMD) test of upper arm occlusion by the brachial artery.
Materials and methods. In the non-invasive study, endothelial dysfunction (ED) was induced with a pneumatic cuff, thereby inflicting compression only on the distal circulation with reactive hyperemia. Manifestation of ED was evaluated by the diameter of the brachial artery (BA) being less than 10% compared to the baseline, or vasoconstriction.
Results. The patients were divided into four groups by the severity of the disease. Group I (n = 262) comprised home-quarantined patients with mild symptoms (HQM); Group II (n = 183), patients hospitalized with moderate symptoms (HMO); Group III (n = 41), patients hospitalized with severe symptoms who required oxygen therapy (HSV); and Group IV (n = 16), patients in the Intensive Care Unit (ICU) hospitalized with critical symptoms (HCR). In HCR (Group IV), the reaction of the BA diameter on the FMD in 100% of cases was vasoconstriction. In HSV (Group III), 37 (90.2%) patients demonstrated a vasospastic reaction of the BA. In HMO (Group II), vasoconstriction was detected in 23 (12.6%) patients, and 29 (15.9%) patients demonstrated a spastic reaction. In HQM (Group I), 27 (10.3%) patients were detected with vasoconstriction, while in 31 patients (11.83%) a BA spastic reaction was recorded.
Conclusions. Endothelium-dependent vasodilation determined by FMD is a practical and affordable method for the detection of endothelial dysfunction in post-COVID-19 patients and allows identification of patients with a higher risk of cardiovascular complications.
References
Huertas, A., Montani, D., Savale, L., Pichon, J., Tu, L., Parent, F., Guignabert, C., & Humbert, M. (2020). Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? European Respiratory Journal, 56(1), 2001634. https://doi.org/10.1183/13993003.01634-2020.
Page, A., Liles, W. (2013). Biomarkers of endothelial activation/dysfunction in infectious diseases. Virulence, 4(6), 507–516. https://doi.org/10.4161/viru.24530.
Pons, S., Fodil, S., Azoulay, E., & Zafrani, L. (2020). The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Critical Care, 24(1). https://doi.org/10.1186/s13054-020-03062-7.
Thijssen, J., Black, A., Pyke, E., Padilla, J., G., Harris, A., Parker, B., Widlansky, E., Tschakovsky, E., Green, D. (2010). Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. AJP Heart and Circulatory Physiology, 300(1), H2–H12. https://doi.org/10.1152/ajpheart.00471.2010.
Varga, Z., Flammer, A. J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A. S., Mehra, M. R., Schuepbach, R. A., Ruschitzka, F., & Moch, H. (2020). Endothelial cell infection and endotheliitis in COVID-19. The Lancet, 395(10234), 1417–1418. https://doi.org/10.1016/s0140-6736(20)30937-5.
Rodriguez-Miguelez, P., Seigler, N., & Harris, A. (2016). Ultrasound assessment of endothelial function: a technical guideline of the flow-mediated dilation test. Journal of Visualized Experiments, (110). https://doi.org/10.3791/54011.
Biel, V., Novák, J., Pluháček, L., & Špác, J. (2019). Flow mediated dilation - its role and importace in screening of cardiovascular disease risk. Interní Medicína Pro Praxi, 21(2), 92–96. https://doi.org/10.36290/int.2019.014
Newly discovered way of the function of Cardio-Vascular system and the latest theory of the development of hypertension and other Cardio-Vascular diseases. (2017). Journal of Clinical Review & Case Reports, 2(2). https://doi.org/10.33140/jcrc/02/02/00007
Venher, I., Kostiv, S., Selskiy, B., Faryna, I., Orlov, M., Tsiupryk, N., Kovalskiy D. (2022). Intraoperative levels of coagulation factors in patients treated with open and endovascular revascularization of occluded tibial arteries. Georgian medical news, 323, 11-17. ISSN 15120112.
Marushchak, M., Krynytska, I., Homeliuk, T., Vayda, A., Kostiv, S., Blikhar, V. (2024). Charlson comorbidity index and the severity of community-acquired pneumonia caused by SARS-COV-2: A retrospective analysis. Dental and Medical Problems, 61(2), 173–179. https://doi.org/10.17219/dmp/166666.
Patelis, N. et al. (2021). Vascular e-Learning During the COVID-19 Pandemic: The EL-COVID Survey. Annals of Vascular Surgery, 777, 63-70. https://doi.org/10.1016/j.avsg.2021.08.001.
Kostiv, S., Venher, I., Maslii, B., Selskiy, B., Tsiupryk, N., Faryna, I., Orlov, M. (2021). Formation of outflow pathways in patients with combined stenotic-occlusive lesions of the femoral and tibial arterial segments. Clinical and Preventive Medicine, 4(18), 38-44. https://doi.org/ 10.31612/2616-4868.4(18).2021.06.
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020a). COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet, 395(10229), 1033–1034. https://doi.org/10.1016/s0140-6736(20)30628-0.
Nagashima, S., Mendes, M. C., Martins, A. P. C., Borges, N. H., Godoy, T. M., De Noronha, L. (2020). Endothelial dysfunction and thrombosis in patients with COVID-19—Brief report. Arteriosclerosis Thrombosis and Vascular Biology, 40(10), 2404–2407. https://doi.org/10.1161/atvbaha.120.314860.
Haffke, M., Freitag, H., Rudolf, G., Seifert, M., Doehner, W., Scherbakov, N., Sotzny, F. (2022). Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). Journal of Translational Medicine, 20(1). https://doi.org/10.1186/s12967-022-03346-2.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

